With excellent academic centers and a thriving start-up scene, Switzerland’s biotech scene has garnered significant interest in recent years. However, without being a priority for EU funds, the sector remains reliant on foreign cash and needs a funding push from within to boost success.

AstraZeneca is touting Ultomiris’ future potential in neurological conditions as it struggles to convert patients from predecessor Soliris in one of its indications. 

The UK major will work with the US biotech to develop up to three precision medicines targeting cancer proteins previously thought undruggable via conventional methods.

Biogen pushes ahead with approval submission in potentially large Japanese market, despite the negative views of a recent advisory committee in the US.